News - ThromboGenics, Bayer

Filter

Current filters:

ThromboGenicsBayer

Popular Filters

1 to 25 of 334 results

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

01-04-2014

German drug major Bayer presented new analyses from the pivotal ROCKET AF and EINSTEIN clinical trials…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

Bayer’s Adempas gains EU clearance for two forms of PAH

Bayer’s Adempas gains EU clearance for two forms of PAH

31-03-2014

Following a previous positive opinion from the European Medicines Agency’s advisory committee, the…

AdempasBayerEuropePharmaceuticalRegulationRespiratory and Pulmonary

Bayer Healthcare to invest 100 million euros to expand capacity in China

Bayer Healthcare to invest 100 million euros to expand capacity in China

31-03-2014

The HealthCare division of Germany’s Bayer will invest around 100 million euros ($137.5 million) to…

Asia-PacificBayerChinaFinancialPharmaceuticalProduction

Transgene, Lee’s Pharma and SillaJen confirm clinical development plan for Pexa-Vec

27-03-2014

France’s Transgene, Hong Kong-based Lee’s Pharmaceutical and South Korea’s SillaJen have unveiled…

BayerLee's PharmaceuticalNexavarOncologyPexa-VecPharmaceuticalResearchSillaJenTransgene

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo

24-03-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

ThromboGenics announces 2013 growth thanks to Jetrea sales

ThromboGenics announces 2013 growth thanks to Jetrea sales

18-03-2014

Belgium-based biopharma firm ThromboGenics has released its financial results for the full year 2013,…

BelgiumBiotechnologyFinancialJetreaOphthalmicsThromboGenics

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Bayer foresees 8% pa sales growth for pharma through 2016

Bayer foresees 8% pa sales growth for pharma through 2016

13-03-2014

Germany’s Bayer expects strong growth for its pharmaceutical business as a result of a number of new…

AdempasBayerEyleaFinancialPharmaceuticalStivargaXareltoXofigo

Bayer to invest 500 million-euro-plus in hemophilia products manufacturing in Germany

Bayer to invest 500 million-euro-plus in hemophilia products manufacturing in Germany

12-03-2014

German pharma major Bayer revealed yesterday that it plans an investment of more than 500 million euros…

BayerFinancialGermanyHematologyNorthern EuropePharmaceuticalProduction

Nexavar disappoints in Ph III liver cancer study

Nexavar disappoints in Ph III liver cancer study

11-03-2014

German pharma major Bayer and Onyx Pharmaceuticals, now a subsidiary of US biotech firm Amgen say that…

AmgenBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

11-03-2014

US biotech firm KYTHERA Biopharmaceuticals says it has re-acquired all rights outside of the USA and…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsLicensingNorth AmericaPharmaceutical

ThromboGenics to begin Jetrea study in USA

ThromboGenics to begin Jetrea study in USA

04-03-2014

Belgium-based biopharma firm ThromboGenics will soon initiate a US Phase IV study with Jetrea (ocriplasmin).

AlconBelgiumJetreaOphthalmicsPharmaceuticalResearchThromboGenics

Bayer submits marketing authorization for Eylea in Japan

Bayer submits marketing authorization for Eylea in Japan

03-03-2014

US biotech firm Regeneron Pharmaceuticals and partner Bayer’s Japanese subsidiary Bayer Yakuhin have…

BayerEyleaJapanOphthalmicsPharmaceuticalRegeneronRegulation

Bayer results boosted by strong pharma performance

Bayer results boosted by strong pharma performance

28-02-2014

Germany’s Bayer this morning posted financial results for 2013, showing that group sales for the year…

BayerFinancialPharmaceutical

Bayer to buy Chinese OTC/TCM drugmaker Dihon Pharma

27-02-2014

Germany’s leading pharma firm Bayer says it plans to acquire 100% of Dihon Pharmaceutical, a privately…

BayerDihon PharmaceuticalMergers & AcquisitionsPharmaceutical

Way clear for Bayer to complete Algeta acquisition

26-02-2014

The way is now clear for Germany’s Bayer to acquire Norwegian pharmaceutical company Algeta, under…

AlgetaBayerMergers & AcquisitionsOncologyPharmaceuticalXofigo

UK’s NICE gives green light to Bayer’s Eylea in final guidance

26-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final guidance…

BayerEyleaNorthern EuropeOphthalmicsPharmaceuticalPricingRegulationUK

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Positive Ph III results with Bayer’s long-acting recombinant factor VIII product BAY94-9027

Positive Ph III results with Bayer’s long-acting recombinant factor VIII product BAY94-9027

18-02-2014

Germany’s Bayer has released positive results from the PROTECT VIII trial evaluating the company’s…

BAY94-9027BayerHematologyPharmaceuticalResearch

X-Chem licenses drug discovery program to Bayer

X-Chem licenses drug discovery program to Bayer

17-02-2014

X-Chem Inc, a privately held US biotechnology company focused on applying its innovative drug discovery…

BayerBiotechnologyLicensingOncologyX-Chem

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

14-02-2014

There was further negative news for Germany’s Bayer and partner US health care giant Johnson & Johnson,…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationUSAXarelto

Bayer gets “green light” for new transparent low dose contraceptive patch in the EU

Bayer gets “green light” for new transparent low dose contraceptive patch in the EU

14-02-2014

Germany’s Bayer says it has successfully concluded the decentralized European registration procedure…

BayerethinylestradiolEuropegestodenePharmaceuticalRegulationReproductive

FDA advisory panel ambivalent on NSAID cardiovascular risk

FDA advisory panel ambivalent on NSAID cardiovascular risk

12-02-2014

The US Food and Drug Administration’s joint Arthritis Advisory Committee and Drug Safety and Risk Management…

Anti-Arthritics/RheumaticsBayerNaproxenNeurologicalNorth AmericaPfizerPharmaceuticalUSA

1 to 25 of 334 results

Back to top